Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib versus dupilumab in adults with moderate to severe atopic dermatitis on background topical therapy
NL-OMON49637Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Abrocitinib plus dupilumab-matching placebo with Dupilumab plus abrocitinib-matching placebo (2 arms). Primary endpoints: Peak Pruritus Numerical Rating Scale response at Week 2 and EASI-75 response at Week 4. Planned start Apr 2020; status: withdrawn.
02
Drugs
abrocitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON49637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49637.